Literature DB >> 16569885

Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States.

Mathias W R Pletz1, Ardaman P Shergill, Lesley McGee, Bernard Beall, Cynthia G Whitney, Keith P Klugman.   

Abstract

By use of a PCR-restriction fragment length polymorphism assay, we screened 496 levofloxacin-susceptible invasive pneumococcal strains (MIC<or=2 mg/liter) for quinolone resistance-determining region mutations known to confer fluoroquinolone resistance. Among those with a levofloxacin MIC of 2 mg/liter, 16.2% of isolates recovered from nursing home residents and 6.4% from non-nursing home residents had first-step mutations.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16569885      PMCID： PMC1426940          DOI： 10.1128/AAC.50.4.1561-1563.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  An extended PCR-RFLP assay for detection of parC, parE and gyrA mutations in fluoroquinolone-resistant Streptococcus pneumoniae.

Authors:  Rodrigo Alonso; Marc Galimand; Patrice Courvalin
Journal:  J Antimicrob Chemother       Date:  2004-03-10       Impact factor: 5.790

2.  Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.

Authors:  Todd A Davies; Alan Evangelista; Sharon Pfleger; Karen Bush; Daniel F Sahm; Raul Goldschmidt
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Screening of large numbers of Streptococcus pneumoniae isolates for mutations associated with fluoroquinolone resistance using an oligonucleotide probe assay.

Authors:  Todd A Davies; Raul Goldschmidt
Journal:  FEMS Microbiol Lett       Date:  2002-12-17       Impact factor: 2.742

4.  Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  B Perichon; J Tankovic; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Authors:  X S Pan; J Ambler; S Mehtar; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.

Authors:  Stephen H Gillespie; Leroy L Voelker; Jane E Ambler; Chris Traini; Anne Dickens
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

7.  Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.

Authors:  Mathias W R Pletz; Lesley McGee; James Jorgensen; Bernard Beall; Richard R Facklam; Cynthia G Whitney; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

8.  Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States.

Authors:  L K McDougal; J K Rasheed; J W Biddle; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

9.  Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors:  Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.

Authors:  Sue Lim; Darrin Bast; Allison McGeer; Joyce de Azavedo; Donald E Low
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883
View more
  7 in total

1.  Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Daniel E Rozen; Lesley McGee; Bruce R Levin; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005.

Authors:  Margaret Ip; Shirley S L Chau; Fang Chi; Edmund S C Cheuk; Helen Ma; Raymond W M Lai; Paul K Chan
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

Review 3.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

Review 4.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Whole Genome Sequencing of 39 Invasive Streptococcus pneumoniae Sequence Type 199 Isolates Revealed Switches from Serotype 19A to 15B.

Authors:  Oliwia Makarewicz; Marie Lucas; Christian Brandt; Leonie Herrmann; Andreas Albersmeier; Christian Rückert; Jochen Blom; Alexander Goesmann; Mark van der Linden; Jörn Kalinowski; Mathias W Pletz
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

6.  Deciphering the distance to antibiotic resistance for the pneumococcus using genome sequencing data.

Authors:  Fredrick M Mobegi; Amelieke J H Cremers; Marien I de Jonge; Stephen D Bentley; Sacha A F T van Hijum; Aldert Zomer
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

7.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.